Publications scientifiques

An endothelial activin A-bone morphogenetic protein receptor type 2 link is overdriven in pulmonary hypertension

Auteurs : Ryanto GRT, Ikeda K, Miyagawa K, Tu L, Guignabert C, Humbert M, Fujiyama T, Yanagisawa M, Hirata KI, Emoto N.

Sources : Nat Commun. 2021 Mar 19;12(1):1720. Doi: 10.1038/s41467-021-21961-3.

Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases

Auteurs : Cottin V, Richeldi L, Rosas I, Otaola M, Song JW, Tomassetti S, Wijsenbeek M, Schmitz M, Coeck C, Stowasser S, Schlenker-Herceg R, Kolb M; INBUILD Trial Investigators.

Sources : Respir Res. 2021 Mar 16;22(1):84. doi: 10.1186/s12931-021-01668-1.

Risk Stratification in Pulmonary Arterial Hypertension : Do Not Forget the Patient Perspective

Auteurs : Humbert M, Lau EMT

Sources : Am J Respir Crit Care Med. 2021 Mar 15;203(6):675-677. Doi: 10.1164/rccm.202012-4350ED.

Regulation of immune cells in lung fibrosis: the reign of regnase-1 ?

Auteurs : Froidure A, Crestani B.

Sources : Eur Respir J. 2021 Mar 11;57(3):2004029.

Immune checkpoint blockade for patients with lung cancer and idiopathic pulmonary fibrosis

Auteurs : Duchemann B, Pluvy J, Crestani B, Zalcman G, Nunes H.

Sources : Eur J Cancer. 2021 Mar;145:179-182.

Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry

Auteurs : Ghofrani HA, Gomez Sanchez MA, Humbert M, Pittrow D, Simonneau G, Gall H, Grünig E, Klose H, Halank M, Langleben D, Snijder RJ, Escribano Subias P, Mielniczuk LM, Lange TJ, Vachiéry JL, Wirtz H, Helmersen DS, Tsangaris I, Barberá JA, Pepke-Zaba J, Boonstra A, Rosenkranz S, Ulrich S, Steringer-Mascherbauer R, Delcroix M, Jansa P, Šimková I, Giannakoulas G, Klotsche J, Williams E, Meier C, Hoeper MM; NEW COLLABORATORS LIST.

Sources : Respir Med. 2021 Mar;178:106220. Doi: 10.1016/j.rmed.2020.106220.

Characteristics and Long-term Outcomes of Pulmonary Venoocclusive Disease Induced by Mitomycin C.

Auteurs : Certain MC, Chaumais MC, Jaïs X, Savale L, Seferian A, Parent F, Georges M, Favrolt N, Bourdin A, Boissin C, Cottin V, Traclet J, Renard S, Noel V, Picard F, Girerd B, Ghigna MR, Perros F, Sitbon O, Bonniaud P, Humbert M, Montani D.

Sources : Chest. 2021 Mar;159(3):1197-1207. Doi: 10.1016/j.chest.2020.09.238.

Reversible pulmonary hypertension associated with multivisceral Whipple’s disease

Auteurs : Camboulive A, Jutant EM, Savale L, Jaïs X, Sitbon O, Mussini C, Bénichou J, Lagier JC, Humbert M, Montani D.

Sources : Eur Respir J. 2021 Feb 25;57(2):2003132. Doi: 10.1183/13993003.03132-2020.

Pulmonary Vascular Resistance in Pulmonary Arterial Hypertension: La Pièce de Résistance ?

Auteurs : Weatherald J, Boucly A, Savale L, Jaïs X, Montani D, Humbert M, Sitbon O.

Sources : Am J Respir Crit Care Med. 2021 Feb 15;203(4):524-525. Doi: 10.1164/rccm.202009-3664LE.

Safety and efficacy of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis and carrying a telomere-related gene mutation

Auteurs : Justet A, Klay D, Porcher R, Cottin V, Ahmad K, Molina Molina M, Nunes H, Reynaud-Gaubert M, Naccache JM, Manali E, Froidure A, Jouneau S, Wemeau L, Andrejak C, Gondouin A, Hirschi S, Blanchard E, Bondue B, Bonniaud P, Tromeur C, Prévot G, Marchand-Adam S, Funke-Chambour M, Gamez AS, Ba I, Papiris S, Grutters J, Crestani B, van Moorsel C, Kannengiesser C, Borie R; OrphaLung Network.

Sources : Eur Respir J. 2021 Feb 11;57(2):2003198.